We are live on ! Find out more

Veracyte

VCYT

Market cap $3.64B

45.23 USD

+1.63

3.74%

At close Updated Oct 9, 4:00 PM EDT

1 day

3.74%

5 days

-1.14%

1 month

3.12%

3 months

-23.73%

6 months

44.27%

Year to date

6.7%

1 year

29.49%

5 years

8.86%

10 years

458.4%

About: Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Employees: 755

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36.8%

Neutral 42.1%

Negative 21.1%

Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Zacks Investment Research

Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?

Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

Zacks Investment Research

3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes

GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.

3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Zacks Investment Research

Is it Worth Adding Veracyte Stock to Your Portfolio Now?

VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.

Is it Worth Adding Veracyte Stock to Your Portfolio Now?

Zacks Investment Research

VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?

Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.

VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?

Zacks Investment Research

Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround

Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround

See News Rankings

Price charts implemented using Lightweight Charts™